<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837885</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/47</org_study_id>
    <nct_id>NCT04837885</nct_id>
  </id_info>
  <brief_title>Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases</brief_title>
  <acronym>LUTARTERIAL</acronym>
  <official_title>&quot;Imaging With 68Ga-DOTA-peptides and Peptide Receptor Radionuclide Therapy With 177Lu-DOTA-peptides of Gastroenteropancreatic Neuroendocrine Tumors: Interest of Intra-arterial Hepatic Infusion in Patients With Dominant Liver Metastases&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of liver metastases in neuroendocrine neoplasms is challenging. Peptide&#xD;
      receptor radionuclide therapy with radiolabeled somatostatin analogs (SSA) is one of the most&#xD;
      promising therapeutic options. As liver is the most frequent site of metastatic disease, our&#xD;
      project proposes to compare administration of radiolabeled SSA by arterial intrahepatic&#xD;
      infusion (experimental approach) vs intravenous administration (conventional). Evaluation&#xD;
      will be made by (i) comparing 68Ga-DOTA-peptides uptake after intra-hepatic versus&#xD;
      intravenous route (imaging), (ii) by evaluating the safety of an additional intra-hepatic&#xD;
      administration of therapeutic radiolabeled SSA (therapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver metastases of neuroendocrine tumors of gastro-entero-pancreatic origin are one of the&#xD;
      most limiting factors of patient survival. Peptide receptor radionuclide therapy with&#xD;
      radiolabeled somatostatin analogs (SSA) such as LUTATHERA® represents now a major therapeutic&#xD;
      option. As far as these metastases are mainly perfused by the hepatic artery, it could be&#xD;
      relevant to deliver the treatment by intra-hepatic route, in order to achieve a maximized&#xD;
      dose to the tumour when compared with a systemic conventional administration, while also&#xD;
      reducing kidney and bone marrow toxicity. By using radiolabeled SSA for imaging and therapy,&#xD;
      the present project aims to compare the uptake of 68Ga-DOTA-peptides after intra-hepatic&#xD;
      versus intravenous injections for targeted liver metastases, as well as for dose limiting&#xD;
      organs (kidney, spleen, healthy liver, bone marrow) and extra-hepatic lesions if present. We&#xD;
      will also evaluate whether the intra-hepatic infusion of one treatment dose of LUTATHERA®&#xD;
      after conventional treatment by 4 intravenous administrations, is safe.&#xD;
&#xD;
      Following 4 intravenous administrations of LUTATHERA® in GEP-NET with dominant liver&#xD;
      metastases, patients who gave informed consent will be enrolled for 2 PET-scans, the first&#xD;
      one after intra-hepatic injection of 68Ga-DOTA-peptides and the second one after intravenous&#xD;
      injection for purpose of uptake comparison by 5 liver metastases chosen by radiologists on&#xD;
      MRI.&#xD;
&#xD;
      In 10 patients who meet a predefined enhancement ratio of 3, a 5th dose of LUTATHERA® will be&#xD;
      administered by intra-arterial hepatic injection. (Based on literature data, an average&#xD;
      enhancement ratio of 3.75 is expected from intra-arterial injection compared to intravenous&#xD;
      results; Kratochwil 2010). Those 10 patients will be evaluated for 177Lu-DOTA-peptide&#xD;
      activity and residence time by SPECT/CT imaging.&#xD;
&#xD;
      Follow-up through 18 months will include clinical examination, MRI and CT scan, as usually&#xD;
      performed in these clinical settings and progression&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value (SUVmax) on liver metastases</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standardized uptake value (SUVmax) on liver metastases</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on healthy liver</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on healthy liver</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on kidneys</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on kidneys</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on bone marrow</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on bone marrow</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on spleen</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on spleen</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on associated extra-hepatic metastases</measure>
    <time_frame>Day 0 (First PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on associated extra-hepatic metastases obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized uptake value (SUVmax) on associated extra-hepatic metastases</measure>
    <time_frame>Day 3 (second PET/CT)</time_frame>
    <description>Standardized uptake value (SUVmax) on associated extra-hepatic metastases obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>177Lu-DOTA-peptide dosimetry</measure>
    <time_frame>Day 18</time_frame>
    <description>Absorbed dose in different tissue of the 5 hepatic targets, possible extra-hepatic lesions and healthy organs (healthy liver, kidney, bone marrow, spleen)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neuroendocrine Tumor</condition>
  <condition>Liver Metastases</condition>
  <condition>Neuroendocrine Gastroenteropancreatic Tumour</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTA-peptides PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-DOTA-peptides injections for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUTATHERA® by intra-arterial hepatic injection (IAH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One treatment dose of LUTATHERA® by intra-arterial hepatic injection after conventional treatment by 4 intravenous administrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection</intervention_name>
    <description>Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)</description>
    <arm_group_label>68Ga-DOTA-peptides PET/CT</arm_group_label>
    <arm_group_label>LUTATHERA® by intra-arterial hepatic injection (IAH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection</intervention_name>
    <description>intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)</description>
    <arm_group_label>68Ga-DOTA-peptides PET/CT</arm_group_label>
    <arm_group_label>LUTATHERA® by intra-arterial hepatic injection (IAH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUTATHERA® by intra-arterial hepatic (IAH) injection</intervention_name>
    <description>One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.&#xD;
The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations</description>
    <arm_group_label>LUTATHERA® by intra-arterial hepatic injection (IAH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Scan</intervention_name>
    <description>Scans after completion of LUTATHERA® treatment injection</description>
    <arm_group_label>LUTATHERA® by intra-arterial hepatic injection (IAH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven well differentiated neuroendocrine tumor (NET) of&#xD;
             gastrointestinal or pancreatic origin (GEP).&#xD;
&#xD;
          -  Patients are progressive after treatment with cold somatostatin analog (within 12&#xD;
             months according to RECIST)&#xD;
&#xD;
          -  Patient has received 4 standard of care LUTATHERA® cycles&#xD;
&#xD;
          -  Liver Metastatic disease dominant or exclusive and assessable by RECIST 1.1, and not&#xD;
             amenable to surgical resection after the last cycle&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate kidney and liver function: creatinine clearance ≥ 50 mL/min, ALT/AST ≤ 2,5x&#xD;
             the upper limit of normal&#xD;
&#xD;
          -  With no evidence of hematologic alteration after 4 LUTATHERA® cycles: hemoglobin ≥ 8&#xD;
             g/dL, neutrophils ≥ 1500/ mm3, platelets ≥ 100.000/mm3&#xD;
&#xD;
          -  Age ≥ 18 years, no superior limit&#xD;
&#xD;
          -  Contraception required in pre-menopausal female and men for at least 6 months after&#xD;
             the last LUTATHERA ® injection.&#xD;
&#xD;
          -  Patient´s signed written informed consent&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with complete response defined by the absence of lesion according to RECIST&#xD;
             1.1 realized during morphological imaging at inclusion (chest-abdomen-pelvis CT scan&#xD;
             and hepatic MRI)&#xD;
&#xD;
          -  No residual uptake according to standard 177-Lu scintigraphy performed in the clinical&#xD;
             routine 24 hours after each LUTATHERA IV treatment&#xD;
&#xD;
          -  Carcinoid heart disease (LVEF &lt; 40%)&#xD;
&#xD;
          -  Dominant or threatening extrahepatic metastases or that may affect vital prognosis&#xD;
&#xD;
          -  Contraindications to intra-hepatic arterial infusion (coagulation disorders, portal&#xD;
             thrombosis, intra-hepatic biliary tract dilatation, digestive or biliary anastomosis&#xD;
             or fistula, cirrhosis (Child Pugh B8 or C…)&#xD;
&#xD;
          -  Serum albumin &lt;3.0 g/dL unless prothrombin time is within the normal range.&#xD;
&#xD;
          -  Heart failure, myocardial infarction, stroke, uncontrolled arterial hypertension under&#xD;
             optimal treatment (≥ 160/95 mmHg), pulmonary embolism or revascularization procedure,&#xD;
             unstable angina pectoris, uncontrolled cardiac arrhythmia, and clinically significant&#xD;
             bradycardia during the last 12 months.&#xD;
&#xD;
          -  Individuals under legal protection or unable of giving their informed consent&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Currently participating to another clinical research protocol&#xD;
&#xD;
          -  Individuals under legal protection or unable of giving their informed consent&#xD;
&#xD;
          -  MRI scan contraindicated&#xD;
&#xD;
          -  LUTATHERA® contraindicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghoufrane TLILI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghoufrane TLILI, Dr</last_name>
    <phone>05 57 65 64 08</phone>
    <email>ghoufrane.tlili@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Macary Guillaume</last_name>
    <phone>05 57 62 32 52</phone>
    <email>guillaume.macary@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yann GODBERT, Dr</last_name>
      <email>y.godbert@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie du Gard (ICG) - CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent BOUDOUSQ, Dr</last_name>
      <email>vincent.boudousq@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ghoufrane TLILI, Dr</last_name>
      <phone>05 57 65 64 08</phone>
      <email>ghoufrane.tlili@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Guillaume Macary</last_name>
      <phone>05 57 62 32 52</phone>
      <email>guillaume.macary@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Ghoufrane TLILI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire du cancer de Toulouse (IUCT) Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederic Courbon, Pr</last_name>
      <email>courbon.frederic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine tumour</keyword>
  <keyword>Neuroendocrine gastroenteropancreatic (GEP) tumour</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>68Ga- DOTA-peptides PET CT</keyword>
  <keyword>177Lutetium-Octreotate</keyword>
  <keyword>Peptide Receptor Radionuclide Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

